VistaGen completes PALISADE-4 phase 3 study of fasedienol for social anxiety

May 8, 2026 7:30 AM

VistaGen (NASDAQ: VTGN) announced the completion of the last patient visit in the randomized portion of its PALISADE-4 Phase 3 ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found